Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryohei Ohtani

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 27, 2018
Serum anti-John Cunningham virus antibody seroprevalence and index among Japanese patients with neuromyelitis optica spectrum disordersShinji Aoyama, Masahiro Mori, Akiyuki Uzawa, et al.
Journal of Neurology|March 14, 2018
Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment durationShinji Aoyama, Masahiro Mori, Akiyuki Uzawa, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 3, 2018
Risk factors for fingolimod-induced lymphopenia in multiple sclerosisRyohei Ohtani, Masahiro Mori, Tomohiko Uchida, et al.
Journal of the Neurological Sciences|June 25, 2019
Relapse numbers and earlier intervention by disease modifying drugs are related with progression of less brain atrophy in patients with multiple sclerosisHiroki Masuda, Masahiro Mori, Shigeki Hirano, et al.
Scientific Reports|March 2, 2023
Elevated serum levels of bone morphogenetic protein-9 are associated with better outcome in AQP4-IgG seropositive NMOSDHiroki Masuda, Masahiro Mori, Akiyuki Uzawa, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 4, 2024
Long-term disability progression in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a retrospective analysis of 101 patientsAkiyuki Uzawa, Masahiro Mori, Hiroki Masuda, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 7, 2019
Peripheral blood helper T cell profiles and their clinical relevance in MOG-IgG-associated and AQP4-IgG-associated disorders and MSJia Liu, Masahiro Mori, Kazuo Sugimoto, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 24, 2024
Contributions of CSF interleukin-6 elevation to the pathogenesis of myelin oligodendrocyte glycoprotein antibody-associated diseaseAkiyuki Uzawa, Masahiro Mori, Hiroki Masuda, et al.
Neurology. Clinical Practice|September 6, 2021
Cryptococcal Meningitis in a Fingolimod-Treated Patient: Positive Antigen Test a Year Before OnsetReiji Aoki, Masahiro Mori, Yo-Ichi Suzuki, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 7, 2021
Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorderHiroki Masuda, Masahiro Mori, Shigeki Hirano, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 27, 2018
Serum anti-John Cunningham virus antibody seroprevalence and index among Japanese patients with neuromyelitis optica spectrum disordersShinji Aoyama, Masahiro Mori, Akiyuki Uzawa, et al.
Journal of Neurology|March 14, 2018
Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment durationShinji Aoyama, Masahiro Mori, Akiyuki Uzawa, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 3, 2018
Risk factors for fingolimod-induced lymphopenia in multiple sclerosisRyohei Ohtani, Masahiro Mori, Tomohiko Uchida, et al.
Journal of the Neurological Sciences|June 25, 2019
Relapse numbers and earlier intervention by disease modifying drugs are related with progression of less brain atrophy in patients with multiple sclerosisHiroki Masuda, Masahiro Mori, Shigeki Hirano, et al.
Scientific Reports|March 2, 2023
Elevated serum levels of bone morphogenetic protein-9 are associated with better outcome in AQP4-IgG seropositive NMOSDHiroki Masuda, Masahiro Mori, Akiyuki Uzawa, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 4, 2024
Long-term disability progression in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a retrospective analysis of 101 patientsAkiyuki Uzawa, Masahiro Mori, Hiroki Masuda, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 7, 2019
Peripheral blood helper T cell profiles and their clinical relevance in MOG-IgG-associated and AQP4-IgG-associated disorders and MSJia Liu, Masahiro Mori, Kazuo Sugimoto, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 24, 2024
Contributions of CSF interleukin-6 elevation to the pathogenesis of myelin oligodendrocyte glycoprotein antibody-associated diseaseAkiyuki Uzawa, Masahiro Mori, Hiroki Masuda, et al.
Neurology. Clinical Practice|September 6, 2021
Cryptococcal Meningitis in a Fingolimod-Treated Patient: Positive Antigen Test a Year Before OnsetReiji Aoki, Masahiro Mori, Yo-Ichi Suzuki, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 7, 2021
Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorderHiroki Masuda, Masahiro Mori, Shigeki Hirano, et al.
Pageof 4